UL131 Antibody

What is the UL131 protein and what role does it play in cytomegalovirus infection?

UL131 is a critical protein component of human cytomegalovirus (HCMV) that forms part of the pentameric complex gH/gL/UL128/UL130/UL131. This complex plays a crucial role in viral entry into specific cell types. While fibroblast entry is mediated by glycoprotein complexes gB, gH/gL/gO, and gM/gN, the entry into epithelial cells, endothelial cells, and macrophages specifically requires the addition of the gH/gL/UL128/UL130/UL131 complex . The UL131 protein is particularly significant as laboratory strains such as AD169 often contain frameshift mutations in the UL131 gene, which impairs their ability to infect epithelial and endothelial cells . Functional expression of UL131 restores the virus's ability to efficiently enter these biologically relevant cell types, demonstrating its essential role in tissue tropism .

What cell types require the gH/gL/UL128-131 complex for efficient CMV entry?

The gH/gL/UL128-131 complex is specifically required for efficient CMV entry into epithelial and endothelial cells, which are biologically relevant for viral transmission and pathogenesis. Research comparing viruses with and without functional UL131 has demonstrated that epithelial cells derived from multiple mucosal tissues show a pronounced requirement for this complex. These include:

• Vaginal epithelial cells

• Cervical epithelial cells

• Foreskin epithelial cells

• Tonsillar epithelial cells

• Bronchial epithelial cells

• Retinal pigment epithelial cells (ARPE-19)

In contrast, fibroblasts (such as MRC-5 cells) can be efficiently infected regardless of the presence of a functional gH/gL/UL128-131 complex . This cell type specificity is significant because mucosal epithelial cells represent critical sites for initial viral infection and transmission, making the complex an important target for preventive strategies .

What methodologies are most effective for generating high-titer neutralizing UL131 antibodies?

Generating high-titer neutralizing antibodies against UL131 requires careful consideration of peptide selection, conjugation strategy, and immunization protocol. Based on research findings, the following methodology has proven effective:

• Peptide selection: Select peptides based on computer algorithms that predict hydrophilic, antigenic, and surface-exposed domains. For UL131, the peptide sequence SDFRRQNRRGGTNKRTT (residues 90-106) has been successfully used .

• Conjugation approach: Synthesize the peptide with a C-terminal cysteine to allow conjugation to keyhole limpet hemocyanin (KLH) using maleimide activation. Optimal conjugates should have peptides comprising 15-30% of the total mass .

• Immunization protocol: For rabbit immunization, begin with 500-1000 μg of KLH-conjugated peptide mixed with Freund's adjuvant, followed by three booster immunizations at 4-6 week intervals with decreasing doses (250 μg, 100 μg, and 50 μg) using Titer-Max Gold adjuvant .

• Validation: Confirm antibody specificity through immunoprecipitation and immunoblotting against native protein. Neutralization capacity should be assessed using a GFP-tagged virus (such as BADrUL131-Y4) on relevant epithelial cell lines with IC50 values calculated by plotting GFP expression against serum dilution .

This approach has been demonstrated to produce antibodies with high neutralizing activity specifically against epithelial cell entry, with titers exceeding 1:1000 in neutralization assays .

How do UL130 and UL131 peptide-induced antibodies compare in their neutralizing potential?

Both UL130 and UL131 peptide-induced antibodies demonstrate potent neutralizing activity against CMV entry into epithelial cells, though with some notable differences in their characteristics and potential applications. Studies have directly compared these antibodies with the following findings:

• Neutralizing titers: Both anti-UL130 and anti-UL131 peptide antibodies achieve high neutralizing titers against CMV, with IC50 values of 1:2889 and 1:5350 respectively in ARPE-19 cells . This indicates that UL131 peptide-induced antibodies may have slightly higher potency.

• Neutralization spectrum: Both antibodies effectively neutralize viral entry into epithelial cells from multiple mucosal tissues, including cervical, foreskin, and bronchial epithelial cells . Neither antibody neutralizes viral entry into fibroblasts.

• Conservation considerations: UL131 peptide is 100% conserved across 29 analyzed CMV strains, while the UL130 peptide shows variation with five different sequence variants identified . This suggests that UL131 antibodies may offer broader cross-strain protection.

• Binding dynamics: When examining the assembly of the gH/gL/UL128-131 complex, UL130 demonstrates direct interactions with UL131, suggesting that these proteins cooperatively enhance their incorporation into the complex .

These comparative findings indicate that while both UL130 and UL131 peptide-induced antibodies can effectively neutralize epithelial cell entry, UL131 antibodies may offer advantages in terms of potency and strain coverage due to the exceptional conservation of the target epitope .

What protein-protein interactions occur during assembly of the gH/gL/UL128-131 complex?

The assembly of the gH/gL/UL128-131 complex involves multiple specific protein-protein interactions that collectively determine the efficiency of complex formation and viral entry into epithelial cells. Studies using HCMV mutants and adenovirus vectors expressing individual components have revealed the following key interactions:

• Independent binding: UL128, UL130, and UL131 can each independently assemble onto gH/gL scaffolds .

• Cooperative binding: The binding of individual UL128-131 proteins to gH/gL significantly affects the binding of other proteins in the complex. Specifically, UL128 increases the binding of both UL130 and UL131 to gH/gL .

• Direct interactions: Several direct protein-protein interactions have been observed:

  • gH/UL130

  • UL130/UL131

  • gL/UL128

  • UL128/UL130

• Cellular trafficking: The export of gH/gL complexes from the endoplasmic reticulum (ER) to the Golgi apparatus and cell surface is dramatically enhanced when all three proteins (UL128, UL130, and UL131) are simultaneously coexpressed with gH/gL .

• Functional requirements: For the production of complexes that can function in viral entry into epithelial and endothelial cells, all three proteins (UL128, UL130, and UL131) must bind simultaneously to gH/gL .

These interactions demonstrate that while individual UL128-131 proteins can bind to gH/gL, the complete pentameric complex is required for efficient intracellular trafficking and incorporation into the virion envelope, which is necessary for epithelial cell entry .

How can researchers differentiate between laboratory and clinical CMV strains using UL131 antibodies?

Researchers can effectively differentiate between laboratory and clinical CMV strains using UL131 antibodies through several methodological approaches:

• Neutralization assays: Laboratory strains such as AD169 and Towne, which have been extensively propagated on fibroblasts, typically harbor mutations in the UL131 gene (such as frameshifts) that prevent formation of functional gH/gL/UL128-131 complexes . By testing the neutralizing capacity of UL131 antibodies on different cell types, researchers can distinguish between:

  • Laboratory strains: Infection of fibroblasts will be unaffected by UL131 antibodies

  • Clinical strains: Infection of both fibroblasts and epithelial cells will occur, but only epithelial cell infection will be neutralized by UL131 antibodies

• Entry efficiency analysis: Using GFP-tagged viruses with repaired UL131 genes (such as BADrUL131-Y4) compared to viruses with UL131 mutations (such as HB15-t178b), researchers can quantify entry efficiency into various cell types. Clinical strains will behave like the repaired laboratory strains, showing efficient entry into epithelial cells .

• Immunoprecipitation studies: UL131 antibodies can be used to immunoprecipitate the gH/gL/UL128-131 complex from viral preparations. Laboratory strains will fail to show UL131 in these complexes, while clinical isolates will demonstrate intact complexes .

This differentiation is critically important for research validity, as laboratory strains with defective UL131 may not accurately represent the biological behavior of clinical isolates, particularly in studies examining viral tropism, pathogenesis, or vaccine development .

What is the potential of UL131 antibodies in developing sterilizing immunity against mucosal CMV infection?

UL131 antibodies show considerable promise for developing sterilizing immunity against mucosal CMV infection, particularly due to their ability to block the initial entry of the virus into mucosal epithelial cells. Several lines of evidence support this potential:

• Mucosal epithelial cell protection: UL131 antibodies potently neutralize CMV entry into epithelial cells derived from tissues relevant to transmission, including vaginal, cervical, foreskin, tonsillar, and bronchial epithelial cells . Since these represent the initial sites of virus contact during transmission, blocking entry at these locations could prevent infection establishment.

• Mechanistic basis: The gH/gL/UL128-131 complex is essential for CMV entry into mucosal epithelial cells. This complex mediates endocytosis followed by low-pH-dependent fusion, which is the entry pathway into biologically relevant epithelial and endothelial cells . UL131 antibodies specifically target this entry mechanism.

• Conservation advantage: The exceptional conservation of the UL131 peptide (100% identity across 29 analyzed strains) suggests that UL131 antibodies would provide broad protection against diverse CMV strains , an essential characteristic for sterilizing immunity.

• Passive immunization precedent: Anti-CMV hyperimmune globulin (HIG) has demonstrated efficacy in preventing CMV disease in solid-organ transplant patients and congenital disease when administered to pregnant women . Research has shown that the major neutralizing antibody component of CMV-HIG is directed at the gH/gL/UL128/UL130/UL131 complex .

• Mucosal antibody potential: Secretory antibodies targeting the epithelial entry pathway have the theoretical potential to provide sterilizing immunity by blocking initial mucosal infection . UL131 antibodies specifically neutralize this pathway.

These findings collectively suggest that vaccine strategies focused on eliciting UL131 antibodies could potentially provide sterilizing immunity by targeting the critical initial steps of mucosal infection, which represents a promising approach for preventing CMV transmission .

What are the comparative advantages of using peptide versus recombinant protein immunogens for generating UL131 antibodies?

The choice between peptide and recombinant protein immunogens for generating UL131 antibodies presents researchers with distinct advantages and limitations that should be considered based on research objectives:

Peptide Immunogens:

• Targeted epitope selection: Peptides allow precise targeting of specific, predicted antigenic regions. For UL131, the peptide SDFRRQNRRGGTNKRTT (residues 90-106) has successfully generated high-titer neutralizing antibodies .

• Conservation advantages: The high conservation of the UL131 peptide (100% identity across 29 strains) ensures broad strain coverage of resulting antibodies .

• Production simplicity: Synthetic peptides can be produced with high purity and in sufficient quantities without the complexities of protein expression systems .

• Conjugation flexibility: Peptides can be readily conjugated to carrier proteins like KLH through the addition of terminal cysteines, enhancing immunogenicity .

• Limitations: Peptide-induced antibodies may recognize linear rather than conformational epitopes, potentially missing some neutralizing determinants.

Recombinant Protein Immunogens:

• Conformational epitopes: Full-length recombinant UL131 protein may better present conformational epitopes that depend on tertiary structure.

• Complex formation challenges: Producing stable, properly folded gH/gL/UL128-131 complexes has proven challenging, as noted in research: "We utilized antigens displayed on cells for the serial depletion of CMV-HIG rather than soluble gH/gL/UL128/UL130/UL131 complex due to the challenges of making significant quantities of homogeneous complex" .

• Native presentation: Literature suggests that "conformational epitopes of viral glycoprotein complexes may be more native on cells than soluble antigens" , indicating potential limitations of recombinant approaches.

• Cell-based expression systems: Adenoviral vectors expressing UL131 in human cells have been used to study protein interactions and could potentially serve as immunization platforms .

The research evidence suggests that peptide-based approaches for UL131 have proven highly effective, with documented success in generating potent neutralizing antibodies against epithelial cell entry . This approach may be particularly advantageous for UL131 given the high conservation of the target peptide and the demonstrated neutralizing capacity of the resulting antibodies.

What experimental systems are most appropriate for evaluating UL131 antibody neutralizing activity?

Evaluating UL131 antibody neutralizing activity requires carefully designed experimental systems that reflect the biological relevance of the gH/gL/UL128-131 complex. Based on published research, the following approaches are most appropriate:

• Cell line selection:

  • Primary target: ARPE-19 (retinal pigment epithelial) cells serve as the standard model for assessing neutralization of epithelial entry .

  • Biologically relevant alternatives: Epithelial cells derived from mucosal tissues relevant to transmission should be included: vaginal, cervical, foreskin, tonsillar, and bronchial epithelial cells .

  • Negative control: MRC-5 fibroblasts should be used to confirm specificity of neutralization for the epithelial entry pathway .

• Virus systems:

  • Reporter viruses: GFP-tagged viruses enable quantitative assessment of infection. BADrUL131-Y4 (AD169-derived with repaired UL131) is ideal as it expresses functional gH/gL/UL128-131 complexes .

  • Control viruses: Paired viruses differing only in UL131 functionality (e.g., HB15-t178b with UL131 mutation) provide essential controls .

• Neutralization assay methodology:

  • Quantification approach: Measuring GFP fluorescence using plate readers provides objective quantification of neutralization .

  • IC50 determination: Calculate 50% inhibitory concentration values by plotting means of triplicate GFP values against log2 serum concentration and determining the midpoint of the resulting curve .

  • Time course: When assessing neutralization in mucosal epithelial cells, observations should extend to 7 days post-infection due to potential differences in viral replication kinetics across cell types .

• Validation methods:

  • Flow cytometry: Confirming antibody depletion efficacy using FACS with cells expressing specific glycoproteins provides a complementary quantitative measure .

  • ELISA: Measuring antibody binding to specific antigens before and after depletion experiments helps verify antibody specificity .

These experimental systems collectively provide a comprehensive evaluation of UL131 antibody neutralizing activity while ensuring biological relevance to CMV transmission and pathogenesis .

What is the UL130 peptide variant distribution across CMV strains and how might this affect antibody development?

UL130 peptide exhibits notable sequence variation across CMV strains, which has significant implications for antibody development targeting this component of the gH/gL/UL128-131 complex. Analysis of 29 distinct CMV strains revealed five UL130 peptide variants with the following distribution pattern:

Table 1: UL130 Peptide Variant Distribution Across CMV Strains

This variability contrasts sharply with the UL131 peptide, which shows 100% sequence conservation across all analyzed strains . The implications for antibody development are significant:

• Cross-reactivity limitations: Antibodies raised against a single UL130 peptide variant may have reduced neutralizing activity against strains expressing different variants .

• Dominant variant targeting: When developing UL130-targeted antibodies, focusing on variant 2 (present in 37.9% of strains) might maximize coverage, but would still miss a significant proportion of circulating strains.

• Multi-epitope strategies: For comprehensive coverage, researchers might need to develop antibodies against multiple UL130 variants or identify conserved epitopes within the variable regions.

• UL131 comparative advantage: The complete conservation of the UL131 peptide makes it potentially superior for broad-spectrum antibody development compared to UL130 .

• Combined approach rationale: Given the direct interactions observed between UL130 and UL131 , a combination of antibodies targeting both proteins might provide synergistic neutralization with broader strain coverage.

These findings suggest that while UL130 antibodies demonstrate potent neutralizing activity, their effectiveness against diverse clinical isolates may be limited by sequence variation. Researchers developing UL130-targeted antibodies should carefully consider which variant(s) to target based on the geographical and clinical distribution of CMV strains relevant to their research or therapeutic objectives .

How do different cell types affect the interpretation of UL131 antibody neutralization assays?

The cell type used in UL131 antibody neutralization assays significantly influences result interpretation, with important implications for research design and translational applications. Research demonstrates several critical cell type-dependent factors:

• Entry pathway specificity: UL131 antibodies specifically neutralize the epithelial/endothelial entry pathway that requires the gH/gL/UL128-131 complex, but have no effect on fibroblast entry . This fundamental difference means:

  • In fibroblasts (e.g., MRC-5): No neutralization occurs regardless of antibody concentration

  • In epithelial cells (e.g., ARPE-19): Potent neutralization with high titers

• Post-entry replication differences: Research has observed varying degrees of viral replication after successful entry across different epithelial cell types:

  • Foreskin and bronchial epithelial cells: Support full replication cycle with viral spread over time

  • Vaginal, cervical, and tonsillar epithelial cells: Show stable GFP expression over time, suggesting potential post-entry blocks to replication

• Sensitivity variations: Different epithelial cell types may show varying sensitivity to neutralization, potentially due to differences in receptor expression levels or post-entry factors .

• Temporal considerations: The optimal time for assessing neutralization varies by cell type:

  • ARPE-19 cells: Neutralization can be reliably assessed at 4-7 days post-infection

  • Mucosal epithelial cells: May require longer observation (7+ days) to accurately assess neutralization

• Translation relevance: For vaccine development or therapeutic applications, using cells derived from anatomically relevant sites of natural infection (e.g., mucosal epithelial cells) provides more physiologically meaningful data than standard laboratory lines .

These findings highlight the importance of thoughtfully selecting cell types for neutralization assays based on specific research questions. Including both fibroblasts and multiple types of epithelial cells derived from relevant tissues provides the most comprehensive assessment of UL131 antibody neutralizing activity and its potential biological significance .

What are the critical factors in designing peptides for generating high-quality UL131 antibodies?

Designing effective peptides for generating high-quality UL131 antibodies requires careful consideration of multiple factors that influence immunogenicity, specificity, and neutralizing capacity. Based on successful research approaches, the following critical factors should be addressed:

• Epitope prediction and selection:

  • Utilize computer algorithms that predict hydrophilic, antigenic, and surface-exposed domains

  • Prioritize regions with charged residues and prolines, which are generally more immunogenic

  • Consider N- or C-terminal positions, which are often more accessible in the native protein

• Sequence conservation analysis:

  • Analyze sequence conservation across multiple CMV strains (the UL131 peptide SDFRRQNRRGGTNKRTT showed 100% conservation across 29 strains)

  • Targeting highly conserved regions increases the likelihood of generating antibodies with broad strain neutralizing capacity

• Peptide length optimization:

  • The successful UL131 peptide was 17 amino acids (residues 90-106) , providing sufficient length to form potential secondary structures while remaining synthetically manageable

  • Typically, peptides of 15-20 amino acids balance immunogenicity with synthesis practicality

• Conjugation strategy:

  • Add a C-terminal cysteine to enable site-specific conjugation to carrier proteins

  • Use maleimide-activated keyhole limpet hemocyanin (KLH) for conjugation

  • Optimize peptide-to-carrier ratio (15-30% of mass should be peptide)

• Native conformation consideration:

  • While linear peptides have proven successful for UL131, consider the potential importance of conformational epitopes

  • The literature suggests "conformational epitopes of viral glycoprotein complexes may be more native on cells than soluble antigens"

• Functional domain targeting:

  • Consider targeting regions involved in complex formation with gH/gL, UL128, and UL130, as these interactions are critical for function

  • The C-terminal region of UL131 (where the successful peptide was derived) may be particularly important for complex assembly

By carefully addressing these factors, researchers can design UL131 peptides that generate antibodies with high specificity, potent neutralizing activity, and broad strain coverage, as demonstrated by the successful generation of anti-UL131 sera with neutralizing titers exceeding 1:5000 .

How might UL131 antibodies contribute to understanding CMV pathogenesis in specific patient populations?

UL131 antibodies offer unique opportunities for investigating CMV pathogenesis in specific patient populations by targeting the epithelial/endothelial entry pathway that is critical for viral transmission and dissemination. These antibodies can contribute to pathogenesis understanding in several key areas:

• Congenital CMV infection:

  • UL131 antibodies could help elucidate how maternal immunity impacts transplacental transmission

  • Research has shown that "anti-CMV hyperimmune globulin (HIG) has demonstrated efficacy in preventing... congenital disease when administered to pregnant women"

  • The discovery that gH/gL/UL128-131 complex is the major target of neutralizing antibodies in HIG suggests UL131-specific antibodies may be particularly important in this context

• Solid organ transplant recipients:

  • UL131 antibodies can be used to investigate epithelial cell-mediated viral dissemination in transplanted organs

  • Differential neutralization of epithelial versus fibroblast entry could explain tissue-specific manifestations of CMV disease

  • The efficacy of CMV-HIG in preventing CMV disease in these patients highlights the potential role of UL131 antibodies in protection

• HIV/AIDS patients:

  • UL131 antibodies could help explain the high prevalence of CMV retinitis in AIDS patients, given that retinal pigment epithelial cells require the gH/gL/UL128-131 complex for infection

  • Using these antibodies to study how HIV-associated immunosuppression affects control of epithelial CMV infection could provide new insights

• Immunocompromised children:

  • Investigating how UL131 antibody levels correlate with mucosal shedding and disease progression in pediatric populations could inform monitoring strategies

  • The conservation of UL131 across strains makes these antibodies particularly valuable for studying diverse clinical isolates in pediatric settings

• Tracking viral evolution under immune pressure:

  • UL131 antibodies can serve as tools to monitor potential escape mutations in the highly conserved UL131 protein under immune pressure

  • Such studies would be particularly relevant in chronically infected immunocompromised patients where prolonged viral replication occurs

These applications leverage the unique properties of UL131 antibodies to provide insights into tissue-specific aspects of CMV pathogenesis that cannot be addressed with traditional approaches targeting fibroblast-tropic viral components .

What experimental approaches are most promising for translating UL131 antibody research into clinical applications?

Translating UL131 antibody research into clinical applications requires thoughtful experimental approaches that bridge basic science findings with therapeutic development. Several promising strategies emerge from the current research:

• Passive immunization optimization:

  • Building on the success of CMV hyperimmune globulin (CMV-HIG), develop monoclonal antibodies specifically targeting UL131

  • Conduct comparative efficacy studies between polyclonal anti-UL131 sera, monoclonal antibodies, and standard CMV-HIG in animal models

  • Assess dose-response relationships and tissue distribution to determine optimal delivery strategies for maximal mucosal protection

• Peptide vaccine development:

  • Leverage the finding that "short peptides from UL130 and UL131 elicit high titer neutralizing antibodies" to design peptide-based vaccines

  • Test prime-boost strategies combining UL131 peptides with other CMV antigens to enhance breadth of protection

  • Compare different adjuvants for their ability to enhance mucosal immunity when used with UL131 peptides

• Vectored vaccine approaches:

  • Utilize the adenoviral expression systems that have successfully expressed UL131 in research settings as potential vaccine vectors

  • Evaluate viral vectors expressing UL131 alone versus combinations with UL128 and UL130 for their ability to induce neutralizing antibodies

  • Assess mucosal delivery of such vectors to target relevant tissues for optimal immunity

• Animal model validation:

  • Confirm that UL131 antibody-mediated protection extends to relevant animal models of CMV transmission

  • Focus particularly on models that reflect mucosal transmission, which is most relevant to UL131's role in epithelial cell entry

  • Include pregnancy models to assess protection against congenital transmission

• Correlates of protection studies:

  • Design prospective studies in high-risk populations to determine if naturally acquired UL131 antibody levels correlate with protection

  • Define threshold titers associated with reduced risk of infection or disease

  • Develop standardized assays for measuring UL131-specific neutralizing antibodies that could be used in clinical settings

These approaches collectively address the translation gap between the promising basic research findings on UL131 antibodies and their potential clinical applications in preventing and treating CMV disease in vulnerable populations .

How do the complex assembly dynamics of gH/gL/UL128-131 inform antibody targeting strategies?

Understanding the complex assembly dynamics of gH/gL/UL128-131 provides critical insights for developing effective antibody targeting strategies. Research into these dynamics reveals several important considerations:

• Interdependent binding influences:

  • UL128, UL130, and UL131 can each independently bind to gH/gL, but their binding efficiency is influenced by the presence of other complex components

  • UL128 significantly enhances the binding of both UL130 and UL131 to gH/gL

  • This suggests that antibodies targeting interaction sites between components could disrupt complex assembly more effectively than those targeting isolated proteins

• Multiple direct protein-protein interactions:

  • Direct interactions between gH/UL130, UL130/UL131, gL/UL128, and UL128/UL130 have been observed

  • These multiple interaction points create opportunities for antibodies to disrupt complex formation at various stages

  • Antibodies targeting interaction interfaces might provide synergistic neutralization when used in combination

• Cellular trafficking requirements:

  • Export of gH/gL complexes from the endoplasmic reticulum to the Golgi apparatus and cell surface is dramatically enhanced when all three proteins (UL128, UL130, and UL131) are simultaneously present

  • Antibodies that prevent proper complex assembly could effectively reduce virion incorporation of the complex even if they don't directly block receptor binding

• Complete complex necessity:

  • All three proteins (UL128, UL130, and UL131) must bind simultaneously to gH/gL for the production of complexes that function in viral entry

  • This suggests that antibodies preventing binding of any single component could potentially neutralize the entire complex function

• Strategic epitope targeting:

  • Rather than generating antibodies against isolated components, designing immunogens that present key interaction interfaces might produce antibodies that more effectively disrupt complex assembly

  • Cell-surface displayed antigens may better represent native conformational epitopes than soluble proteins